Unknown

Dataset Information

0

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy.


ABSTRACT: Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with NSCLC harboring EGFR fusion mutations (EGFR-MACF1 and EGFR-GNAT3) combined with EGFR amplification. Both patients received EGFR-TKI treatment, and 1 of them showed an antitumor response.

SUBMITTER: Wang Z 

PROVIDER: S-EPMC11003264 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

altmetric image

Publications

Case report: <i>EGFR</i> fusion mutation combined with <i>EGFR</i> amplification responds to EGFR-TKI therapy.

Wang Zhulin Z   Huang Chunyao C   Fan Wenbo W   Sun Shaowu S   Li Kaiyuan K   Liu Xu X   Pu Jiangtao J   Zhang Guoqing G   Li Xiangnan X  

Frontiers in oncology 20240325


Given their good antitumor effects, epidermal growth factor receptor (<i>EGFR</i>) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for <i>EGFR</i>-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. <i>EGFR</i> fusion mutations and <i>EGFR</i> amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with NSCLC harboring <i>EGFR</i> fusion mutations (<i>EGFR-MACF1</i> and <i>EGFR-GNAT3</i>) combined with <i>EGFR</i> ampl  ...[more]

Similar Datasets

| S-EPMC7274020 | biostudies-literature
| S-EPMC7379871 | biostudies-literature
| S-EPMC8609241 | biostudies-literature
| S-EPMC9403890 | biostudies-literature
| S-EPMC9659857 | biostudies-literature
| S-EPMC9843351 | biostudies-literature
2019-12-28 | GSE142668 | GEO
| S-EPMC10372607 | biostudies-literature
| S-EPMC8902093 | biostudies-literature
| S-EPMC9552846 | biostudies-literature